Target intelligence / Profile preview

Exo-alpha-sialidase (NanI) (NanI)

Target
NanI
Molecular classification
Enzyme, Glycoside hydrolase, Exo-alpha-sialidase, Glycosidase, Hydrolase
01

Overview

Exo-alpha-sialidase (NanI) is a major extracellular enzyme produced by the bacterium Clostridium perfringens, particularly by strains associated with chronic gastrointestinal diseases. The enzyme functions by cleaving terminal sialic acid residues from host cell surface glycoconjugates and mucus, which serves as a critical virulence mechanism. By releasing free sialic acid, NanI provides a nutrient source that supports bacterial growth and colonization within the competitive environment of the gut. Furthermore, the removal of sialic acids modifies the host cell surface, unmasking or facilitating the binding of potent toxins such as epsilon toxin (Etx) and Clostridium perfringens enterotoxin (CPE), thereby significantly enhancing their cytotoxic effects. Because of its multifaceted role in promoting bacterial fitness and toxin-mediated damage, NanI is considered a promising therapeutic target for anti-virulence strategies aimed at treating clostridial infections.

Other names
NanI sialidaseExo-alpha-sialidaseN-acetylneuraminate glycohydrolaseNeuraminidaseSialidase IClostridium perfringens sialidase
02

Biological functions

Sialic acid metabolismMucus degradationBacterial adherenceIntestinal colonizationToxin binding enhancementBiofilm formationCarbohydrate catabolism
03

Disease associations

InfectionGas gangrene (Clostridial myonecrosis)Antibiotic-associated diarrhea (AAD)Sporadic diarrheaFood poisoningEnteritis necroticans
04

Safety considerations

Cross-reactivity with human sialidases (NEU1, NEU2, NEU3, NEU4)Disruption of host-microbiota sialic acid balanceAlteration of normal mucus barrier functionPotential for bacterial resistance to enzyme inhibitors
05

Interacting drugs

2-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA/Neu5Ac2en)

3 more in the full profile.

06

Biomarkers

nanI gene presence (detected via PCR)Sialidase enzymatic activity in stool samplesNanI protein levelsFree sialic acid levels in the gastrointestinal tract

Beyond the preview

Go deeper on Exo-alpha-sialidase (NanI) (NanI).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exo-alpha-sialidase (NanI) (NanI).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call